ArticleThe journal of headache and pain2021
A universal outcome measure for headache treatments, care-delivery systems and economic analysis.
Article in The journal of headache and pain, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Understanding Data and Opportunities Focused on Value: A Single-Center Experience in Headache Care.Neurology. Clinical practice · 2025Article
- Burden and Unmet Needs in Migraine Patients: Results from the OVERCOME (Spain) Study.Pain and therapy · 2023Article
- Narrative-based medicine in headache disorders.The journal of headache and pain · 2022Article
- Novel Migraine Therapies May Reduce Public and Personal Disadvantages for People with Migraine.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022Article
- The Global Campaign turns 18: a brief review of its activities and achievements.The journal of headache and pain · 2022Review
- The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates.The journal of headache and pain · 2022Review
- Time is of the essence in headache measurement. A response to Gil-Gouveia.The journal of headache and pain · 2022Article
- TIME, to move forward? comment on "a universal outcome measure for headache treatments, care-delivery systems and economic analysis".The journal of headache and pain · 2022Article
- The impact of migraine and probable migraine on productivity loss in Korea: A cross-sectional online survey.PloS one · 2022Article
- The relationship between headache-attributed disability and lost productivity: 2. Empirical evidence from population-based studies in nine disparate countries.The journal of headache and pain · 2021Article
- Structured headache services as the solution to the ill-health burden of headache. 2. Modelling effectiveness and cost-effectiveness of implementation in Europe: methodology.The journal of headache and pain · 2021Article
- Editorial. Valuing headache's solution.The journal of headache and pain · 2021Article
- Breakthroughs on the clinical management of headache and questions that need to be solved.Ibrain · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe first manuscript in this series delineated a model of structured headache services, potentially cost-effective but requiring formal cost-effectiveness analysis (CEA). We envisaged a need for a new outcome measure for this purpose, applicable to all forms of treatment, care and care-delivery systems as opposed to comparisons of single-modality treatments. CONCEPTION AND DELINEATION: A literature review confirmed the lack of any suitable established measure. We prioritised construct validity, simplicity, comprehensiveness and expression in intuitive units. We noted that pain was the key burdensome symptom of migraine and episodic tension-type headache (TTH), that pain above a certain level was disabling, that it was difficult to put economic value to pain but relatively easy to do this for time, a casualty of headache leading to lost productivity. Alleviation of pain to a non-disabling level would be expected to bring restoration of function. We therefore based the measure on time spent in the ictal state (TIS) of migraine or TTH, either as total TIS or proportion of all time. We expressed impact on health, in units of time, as TIS*DW, where DW was the disability weight for the ictal state supplied by the Global Burden of Disease (GBD) studies. If the time unit was hours, TIS*DW yielded hours lived with (or lost to) disability (HLDs), in analogy with GBD's years lived with disability (YLDs). UTILITY ASSESSMENT: Acute treatments would reduce TIS by shortening attack duration, preventative treatments by reducing attack frequency; health-care systems such as structured headache services would have these effects by delivering these treatments. These benefits were all measurable as HLDs-averted. Population-level estimates would be derived by factoring in prevalence, but also taking treatment coverage and adherence into account. For health-care systems, additional gains from provider-training (promoting adherence to guidelines and, therefore, enhancing coverage) and consumer-education (improving adherence to care plans), increasing numbers within populations gaining the benefits of treatments, would be measurable by the same metric.
conclusionsThe new outcome measure expressed in intuitive units of time is applicable to treatments of all modalities and to system-level interventions for multiple headache types, with utility for CEA and for informing health policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.